体内生成SSA/Ro抗原特异性调节性T细胞改善小鼠实验性干燥综合征
本研究在具有干燥综合征样症状的NOD/LtJ小鼠中,采用短暂清除CD4+ T细胞后给予自身抗原特异性肽Ro480的免疫治疗方案。结果显示该联合方案在体内生成SSA/Ro抗原特异性调节性T细胞,可抑制CD4+ T细胞产生干扰素-γ及唾液腺炎症浸润并维持唾液腺功能,作者认为这为干燥综合征治疗提供了新途径。
要点
- 抗CD4单克隆抗体后给予Ro480-494肽可在NOD/LtJ小鼠体内生成SSA/Ro抗原特异性调节性T细胞。
- 该方案可抑制CD4+ T细胞产生干扰素-γ及唾液腺炎症细胞浸润并维持唾液腺功能。
- 作者认为该体内生成抗原特异性调节性T细胞的方法可能对干燥综合征患者有潜在治疗意义。
核心结论
- 在NOD/LtJ小鼠中联合抗CD4单克隆抗体与自身抗原特异性肽Ro480可在体内生成SSA/Ro抗原特异性调节性T细胞,作者认为该发现为干燥综合征治疗提供了新途径,可能对患者有潜在治疗意义。
研究设计与样本
- NOD/LtJ小鼠接受单次抗CD4单克隆抗体治疗,2天后每隔一天腹腔注射Ro480-494共6次。
- 治疗前后每周测定唾液流量,首次抗CD4单克隆抗体治疗后6周处死小鼠,收集唾液腺进行组织学疾病评分与炎症细胞浸润分析、聚合酶链反应检测基因及流式细胞术分析(包括主要组织相容性复合体II类四聚体染色)。
- 另进行调节性T细胞过继转移以研究新生成调节性T细胞在体内的功能。
主要发现
- 抗CD4单克隆抗体与自身抗原特异性肽Ro480联合可在体内生成SSA/Ro抗原特异性调节性T细胞。
- 该SSA/Ro抗原特异性调节性T细胞可抑制CD4+ T细胞产生干扰素-γ、抑制唾液腺炎症浸润并维持唾液腺功能。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sjögren's syndrome (SS) is a systemic autoimmune disease, and T cells play an important role in the initiation and perpetuation of the disease. In this study, we developed an immunotherapy for NOD/LtJ mice with SS-like symptoms by combining a transient depletion of CD4+ T cells with the administration of autoantigen-specific peptide Ro480. METHODS: NOD/LtJ mice were treated with single anti-CD4 monoclonal antibody (mAb) followed 2 days later by a series of 6 intraperitoneal injections of Ro480-494 every other day. Salivary flow rates were determined pre- and posttreatment once a week. Mice were euthanized 6 weeks after the initial anti-CD4 mAb treatment, salivary glands (SGs) were collected for analyses of histologic disease scores and inflammatory cell infiltration, polymerase chain reaction determination of genes was conducted, and flow cytometry analysis including major histocompatibility complex class II tetramer staining of immune cells was performed. In addition, adoptive transfer of Treg cells was administrated to investigate the function of the newly generating Treg cells in vivo. RESULTS: The combination of anti-CD4 mAb with autoantigen-specific peptide Ro480 generated SSA/Ro antigen-specific Treg cells in vivo, which can suppress interferon-γ production of CD4+ T cells and inflammation infiltration in SGs and maintain the function of SGs. CONCLUSION: Our findings provide a new approach to generating antigen-specific Treg cells in vivo for SS treatment, which may have implications for potential therapy for patients with SS.
引用
- Xu J, Liu O, Wang D, et al. In Vivo Generation of SSA/Ro Antigen-Specific Regulatory T Cells Improves Experimental Sjögren's Syndrome in Mice. Arthritis Rheumatol. 2022. PMID: 35606923. doi:10.1002/art.42244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。